Literature DB >> 26521300

IL-28B down-regulates regulatory T cells but does not improve the protective immunity following tuberculosis subunit vaccine immunization.

Yanping Luo1, Xingming Ma1, Xun Liu2, Xiaoling Lu1, Hongxia Niu2, Hongjuan Yu1, Chunxiang Bai2, Jinxiu Peng2, Qiaoyang Xian3, Yong Wang3, Bingdong Zhu4.   

Abstract

Regulatory T cells (Tregs), which could be down-regulated by IL-28B, were reported to suppress T-cell-mediated immunity. The aim of this study was to investigate the role of IL-28B on the immune responses and protective efficacy of a tuberculosis (TB) subunit vaccine. First, a recombinant adenoviral vector expressing mouse IL-28B (rAd-mIL-28B) was constructed; then C57BL/6 mice were immunized with subunit vaccine ESAT6-Ag85B-Mpt64(190-198)-Mtb8.4-HspX (EAMMH) and rAd-mIL-28B together thrice or primed with Mycobacterium bovis bacillus Calmette-Gue'rin (BCG) and boosted by EAMMH and rAd-mIL-28B twice. At last the immune responses were evaluated, and the mice primed with BCG and boosted by subunit vaccines were challenged with virulent Mycobacterium tuberculosis H37Rv to evaluate the protective efficacy. The results showed that rAd-mIL-28B treatment significantly down-regulated the frequency of Tregs at 4 weeks after the last immunization but did not increase the Th1-type immune responses. Moreover, in the regimen of BCG priming and EAMMH boosting, rAd-mIL-28B treatment did not increase the antigen-specific cellular and humoral immune responses, and consequently did not reduce the bacteria load following H37Rv challenge. Instead, it induced more serious pathology reaction. In conclusion, IL-28B down-regulates Tregs following EAMMH vaccination but does not improve the protective immune responses. © The Japanese Society for Immunology. 2015. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  IL-28B; cytokine; immune regulation; regulatory T cells; tuberculosis vaccine

Mesh:

Substances:

Year:  2015        PMID: 26521300      PMCID: PMC4885220          DOI: 10.1093/intimm/dxv061

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  41 in total

Review 1.  The role of programming in memory T-cell development.

Authors:  David Masopust; Susan M Kaech; E John Wherry; Rafi Ahmed
Journal:  Curr Opin Immunol       Date:  2004-04       Impact factor: 7.486

2.  Interleukin-28B polymorphisms are associated with hepatitis C virus clearance and viral load in a HIV-1-infected cohort.

Authors:  L N Clausen; N Weis; K Astvad; K Schønning; M Fenger; H Krarup; J Bukh; T Benfield
Journal:  J Viral Hepat       Date:  2010-11-12       Impact factor: 3.728

3.  Mycobacterium bovis BCG-mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells.

Authors:  Diane J Ordway; Shaobin Shang; Marcela Henao-Tamayo; Andres Obregon-Henao; Laura Nold; Megan Caraway; Crystal A Shanley; Randall J Basaraba; Colleen G Duncan; Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2011-07-27

4.  Antigen delivery to CD11c+CD8- dendritic cells induces protective immune responses against experimental melanoma in mice in vivo.

Authors:  Kirsten Neubert; Christian H K Lehmann; Lukas Heger; Anna Baranska; Anna Maria Staedtler; Veit R Buchholz; Sayuri Yamazaki; Gordon F Heidkamp; Nathalie Eissing; Henry Zebroski; Michel C Nussenzweig; Falk Nimmerjahn; Diana Dudziak
Journal:  J Immunol       Date:  2014-05-14       Impact factor: 5.422

Review 5.  IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties.

Authors:  Katrin Witte; Ellen Witte; Robert Sabat; Kerstin Wolk
Journal:  Cytokine Growth Factor Rev       Date:  2010-07-23       Impact factor: 7.638

Review 6.  IL28B and the control of hepatitis C virus infection.

Authors:  Ashwin Balagopal; David L Thomas; Chloe L Thio
Journal:  Gastroenterology       Date:  2010-10-13       Impact factor: 22.682

7.  Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness.

Authors:  B Bourdin Trunz; Pem Fine; C Dye
Journal:  Lancet       Date:  2006-04-08       Impact factor: 79.321

8.  Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice.

Authors:  Yu Luo; Bingxiang Wang; Lina Hu; Hongjuan Yu; Zejiao Da; Wenwen Jiang; Nannan Song; Yaqing Qie; Honghai Wang; Zhijiao Tang; Qiaoyang Xian; Ying Zhang; Bingdong Zhu
Journal:  Vaccine       Date:  2009-08-25       Impact factor: 3.641

Review 9.  Memory T cell subsets, migration patterns, and tissue residence.

Authors:  Scott N Mueller; Thomas Gebhardt; Francis R Carbone; William R Heath
Journal:  Annu Rev Immunol       Date:  2012-12-03       Impact factor: 28.527

10.  Accelerating the secondary immune response by inactivating CD4(+)CD25(+) T regulatory cells prior to BCG vaccination does not enhance protection against tuberculosis.

Authors:  Kylie M Quinn; Fenella J Rich; Lisa M Goldsack; Geoffrey W de Lisle; Bryce M Buddle; Brett Delahunt; Joanna R Kirman
Journal:  Eur J Immunol       Date:  2008-03       Impact factor: 5.532

View more
  5 in total

1.  Diminished circulating plasma and elevated lymph node culture supernatant levels of IL-10 family cytokines in tuberculous lymphadenitis.

Authors:  Gokul Raj Kathamuthu; Nathella Pavan Kumar; Kadar Moideen; Dhanaraj Baskaran; Syed Hissar; Basavegowdanadoddi M Shrinivasa; Rathinam Sridhar; Subash Babu
Journal:  Cytokine       Date:  2018-06-02       Impact factor: 3.861

Review 2.  Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination.

Authors:  Lakshmi Jayashankar; Richard Hafner
Journal:  Front Immunol       Date:  2016-12-16       Impact factor: 7.561

Review 3.  Regulatory T Cells in Mycobacterium tuberculosis Infection.

Authors:  Paula Cardona; Pere-Joan Cardona
Journal:  Front Immunol       Date:  2019-09-11       Impact factor: 7.561

4.  Synergism therapeutic and immunoregulatory effects of Albendazole + rAd-mIL-28B against Echinococcosis in experiment-infected mice with protoscoleces.

Authors:  Yan Zhang; Jianghua Wang; Qingxia Yang; Zhi Li; Xiaoying Xu; Chong Chen; Zongjie Hou; Qi He; Li Sheng; Xingming Ma; Yanping Luo
Journal:  PLoS Negl Trop Dis       Date:  2021-11-24

5.  Intratumoral IL-28B Gene Delivery Elicits Antitumor Effects by Remodeling of the Tumor Microenvironment in H22-Bearing Mice.

Authors:  Zhi Li; Jianghua Wang; Chong Chen; Qi He; Xiaoying Xu; Zejiao Da; Bo Wang; Meng Wang; Xiaotong Gao; Guochao Zhang; Qi Gao; Xiaoli Si; Yanping Luo; Xingming Ma
Journal:  J Immunol Res       Date:  2022-07-28       Impact factor: 4.493

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.